Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(20):1485; doi:10.1093/jnci/dji388
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Lifetime Risk of Melanoma in CDKN2A Mutation Carriers

Previous reports indicate that lifetime risk of melanoma in CDKN2A mutation carriers is high among people in multiple-case families. Begg et al. (p. 1507) calculated lifetime melanoma risk using the kin–cohort method in 65 CDKN2A mutation carriers who were identified among 3550 probands, case patients with either first or subsequent melanoma, in a population-based study. The authors found that melanoma risk in the carriers was approximately 14% by age 50 years, 24% by age 70 years, and 28% by age 80 years. They conclude that lifetime melanoma risk in CDKN2A mutation . . . [Full Text of this Article]

Early Complications After Radical Prostatectomy

Targeted Immunotherapy and Photodynamic Therapy

Trial of Combination Chemo for Unresectable HCC

Using Yeast to Study Resistance to an Angiogenesis Inhibitor

DNA Methyltransferase Inhibitors as Cancer Therapies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?